(Q48673800)

14 February 2018

title

Health-related quality of life in multiple myeloma patients receiving high-dose chemotherapy with autologous blood stem-cell support (English)

1 reference

14 February 2018

1 reference

1 reference

1 reference

N Gulbrandsen

1

1 reference

14 February 2018

F Wisløff

2

1 reference

14 February 2018

L Brinch

3

1 reference

14 February 2018

K Carlson

4

1 reference

14 February 2018

I M Dahl

5

1 reference

14 February 2018

P Gimsing

6

1 reference

14 February 2018

E Hippe

7

1 reference

14 February 2018

M Hjorth

8

1 reference

14 February 2018

L M Knudsen

9

1 reference

14 February 2018

J Lamvik

10

1 reference

14 February 2018

S Lenhoff

11

1 reference

14 February 2018

E Løfvenberg

12

1 reference

14 February 2018

I Nesthus

13

1 reference

14 February 2018

J L Nielsen

14

1 reference

14 February 2018

I Turesson

15

1 reference

14 February 2018

J Westin

16

1 reference

14 February 2018

Nordic Myeloma Study Group

17

1 reference

14 February 2018

publication date

1 January 2001

1 reference

14 February 2018

published in

Medical Oncology

1 reference

14 February 2018

volume

18

1 reference

14 February 2018

issue

1

1 reference

14 February 2018

page(s)

65-77

1 reference

14 February 2018

Survival in conventionally treated younger (<60 years) multiple myeloma patients: no improvement during two decades. Nordic Myeloma Study Group (NMSG)

cites work

1 reference

12 December 2020

Test/retest study of the European Organization for Research and Treatment of Cancer Core Quality-of-Life Questionnaire

1 reference

12 December 2020

Comparative survival, quality of life and cost-effectiveness of intensive therapy with autologous blood cell transplantation or conventional chemotherapy in multiple myeloma

1 reference

12 December 2020

Impact on survival of high-dose therapy with autologous stem cell support in patients younger than 60 years with newly diagnosed multiple myeloma: a population-based study. Nordic Myeloma Study Group

1 reference

12 December 2020

Effect of interferon on the health-related quality of life of multiple myeloma patients: results of a Nordic randomized trial comparing melphalan-prednisone to melphalan-prednisone + alpha-interferon. The Nordic Myeloma Study Group

1 reference

12 December 2020

Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma.

1 reference

12 December 2020

The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology

1 reference

12 December 2020

The EORTC core quality of life questionnaire (QLQ-C30): validity and reliability when analysed with patients treated with palliative radiotherapy.

1 reference

12 December 2020

Interpreting the significance of changes in health-related quality-of-life scores.

1 reference

12 December 2020

The interpretation of scores from the EORTC quality of life questionnaire QLQ-C30.

1 reference

12 December 2020

Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview of 6,633 patients from 27 randomized trials. Myeloma Trialists' Collaborative Group

1 reference

12 December 2020

Interferon-alpha 2b added to melphalan-prednisone for initial and maintenance therapy in multiple myeloma. A randomized, controlled trial. The Nordic Myeloma Study Group

1 reference

12 December 2020

Measurement of health-related quality of life in multiple myeloma. Nordic Myeloma Study Group.

1 reference

12 December 2020

A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome

1 reference

12 December 2020

Identifiers

DOI

10.1385/MO:18:1:65

1 reference

14 February 2018

Dimensions Publication ID

1045891494

0 references

1 reference

14 February 2018